J.P. Morgan analyst Robbie Marcus maintained a Hold rating on Medtronic (MDT – Research Report) today. The company’s shares opened today at $86.96.
According to TipRanks, Marcus is a 5-star analyst with an average return of 15.1% and a 56.81% success rate. Marcus covers the Healthcare sector, focusing on stocks such as CVRx, Edwards Lifesciences, and Intuitive Surgical.
Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $90.80.
See the top stocks recommended by analysts >>
Based on Medtronic’s latest earnings release for the quarter ending October 31, the company reported a quarterly revenue of $7.98 billion and a net profit of $909 million. In comparison, last year the company earned a revenue of $7.59 billion and had a net profit of $427 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Medtronic (MDT) Company Description:
Founded in 1949, Medtronic Plc, a medical technology company, develops, manufactures, distributes, and sells device-based medical therapies and services worldwide. It operates through four segments, including Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The company is headquartered in Dublin, Ireland.
Read More on MDT: